Glioblastoma News and Research

RSS
Glioblastoma is the most aggressive and malignant form of glioma, a type of primary brain cancer. Surgery is often used to treat gliomas, along with radiation. However, since surgery and radiation fail to cure the disease, doctors may turn to additional radiation or chemotherapy. In early stages glioblastoma tumors often grow without symptoms and therefore can become quite large before symptoms arise. When the tumor becomes symptomatic, tumor growth is usually very rapid and is accompanied by altered brain function, and if left untreated the disease becomes lethal. Although primary treatment is often successful in temporarily stopping the progression of the tumor, glioblastomas almost always recur and become lethal.
EchoBack CAR T-cells could be a game changer in cancer immunotherapy

EchoBack CAR T-cells could be a game changer in cancer immunotherapy

New insights into how disruption of calcium transport leads to autism and intellectual disability

New insights into how disruption of calcium transport leads to autism and intellectual disability

Yale study unlocks potential of lupus-related antibody to target cold tumors

Yale study unlocks potential of lupus-related antibody to target cold tumors

New research reveals potential path forward for glioblastoma treatment

New research reveals potential path forward for glioblastoma treatment

Study highlights the role of ELF4 as a key transcription factor in development, immunity, and oncology

Study highlights the role of ELF4 as a key transcription factor in development, immunity, and oncology

Study links firefighting chemicals to increased glioma risk

Study links firefighting chemicals to increased glioma risk

Circular RNA plays key role in cancer biology and therapy

Circular RNA plays key role in cancer biology and therapy

EZH2 inhibition offers hope for fighting treatment-resistant cancers

EZH2 inhibition offers hope for fighting treatment-resistant cancers

Breakthrough drug more than doubles survival in glioblastoma patients

Breakthrough drug more than doubles survival in glioblastoma patients

Exploring the role of subventricular zone in neural regeneration, neurodegenerative diseases

Exploring the role of subventricular zone in neural regeneration, neurodegenerative diseases

Engineered TIMPs show promise in fighting glioblastoma invasion

Engineered TIMPs show promise in fighting glioblastoma invasion

Researchers uncover how brain tumors reprogram neutrophils to hinder cancer treatment

Researchers uncover how brain tumors reprogram neutrophils to hinder cancer treatment

UCLA scientists discover new approach for treating glioblastoma

UCLA scientists discover new approach for treating glioblastoma

Unveiling the role of FAM20C in disease and cancer treatment

Unveiling the role of FAM20C in disease and cancer treatment

CPRIT awards nearly $23 million to MD Anderson for cancer research projects

CPRIT awards nearly $23 million to MD Anderson for cancer research projects

Innovative brain tumor model offers hope for personalized cancer treatments

Innovative brain tumor model offers hope for personalized cancer treatments

Distinct myeloid-derived suppressor cell populations fuel aggressive brain tumor growth

Distinct myeloid-derived suppressor cell populations fuel aggressive brain tumor growth

UCLA Health receives $1.72 million grant to advance brain tumor research and training

UCLA Health receives $1.72 million grant to advance brain tumor research and training

Breakthrough drug improves treatment of medulloblastoma in mice

Breakthrough drug improves treatment of medulloblastoma in mice

Engineered fat cells starve tumors and prevent cancer growth

Engineered fat cells starve tumors and prevent cancer growth

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.